Children's Medical Center Corporation

Wisconsin Alumni Research Foundation

Stenmark, Paul

Paul Stenmark

Eric Arthur Johnson

Min Dong

Raymond C Stevens

Jérôme Dupuy

Sicai Zhang

Guangyun Lin

Andrew Doxey

William H Tepp

Mark Joseph Jacobson

Provided herein is a novel homolog ofneurotoxin (BoNT) identified in the bacterial species(BoNT/EN). BoNT/EN variants and chimeric toxins comprising domains from BoNT/EN and other BoNTs are also provided. Further provided herein are methods of producing BoNT/EN and its use, e.g., in therapeutic applications.

neurotoxin (BoNT/EN) and derivatives thereof

Provided herein are Clostridialneurotoxin (BoNT) polypeptides of a novel serotype (BoNT/X) and methods of making and using the BoNT polypeptides, e.g., in therapeutic applications.

Botulinum neurotoxin and its derivatives

Disclosed herein are modifiedneurotoxin (BoNT) polypeptides with a modified receptor binding domain ofserotype B, comprising one or more substitution mutations at positions corresponding 1248 or 1249 in serotype B, strain 1. Specific substitution mutations include I1248F, I1248Y, I1248H, I1248W, V1249W, V1249F, V1249Y, V1249H, I1248W/V1249F, I1248W/V1249Y, I1248W/V1249H, I1248F/V1249Y, I1248F/V1249H, I1248Y/V1249H, I1248F/V1249W, I1248Y/V1249W, I1248H/V1249W, I1248Y/V1249F, I1248H/V1249F, or I1248H/V1249Y. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.

Engineered botulinum neurotoxins

Growing community of inventors

Stockholm, Sweden

Paul Stenmark